(Q34210724)

31 July 2017

1 reference

title

Treatment of hepatitis C patients with normal aminotransferases levels (English)

1 reference

31 July 2017

Marcellin P

1

1 reference

31 July 2017

Martinot M

series ordinal

2

1 reference

31 July 2017

Boyer N

series ordinal

3

1 reference

31 July 2017

Lévy S

series ordinal

4

1 reference

31 July 2017

1 November 1999

1 reference

31 July 2017

Clinics in liver disease

1 reference

31 July 2017

3

1 reference

31 July 2017

843-853

1 reference

31 July 2017

4

1 reference

Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV.

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970242-7

7 January 2021

Epidemiology of hepatitis C in the West

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970242-7

7 January 2021

Factors predictive of a beneficial response to therapy of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970242-7

7 January 2021

High Rate of Infectivity and Liver Disease in Blood Donors with Antibodies to Hepatitis C Virus

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970242-7

7 January 2021

Liver histology in hepatitis C infection: a comparison between patients with persistently normal or abnormal transaminases

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970242-7

7 January 2021

The treatment of chronic viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970242-7

7 January 2021

Histological findings in asymptomatic hepatitis C virus carriers

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970242-7

7 January 2021

Predictors of sustained response to alpha interferon therapy in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970242-7

7 January 2021

Detection and quantitation of serum HCV-RNA by branched DNA amplification in anti-HCV positive blood donors

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970242-7

7 January 2021

Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970242-7

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970242-7

7 January 2021

Serum HCV-RNA and liver histologic findings in patients with long-term normal transaminases

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970242-7

7 January 2021

Interferon-alpha 2b therapy in low-activity hepatitis C: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970242-7

7 January 2021

Circulating HCV-RNA, HCV genotype, and liver histology in asymptomatic individuals reactive for anti-HCV antibody and their follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970242-7

7 January 2021

Interferon-alpha therapy for individuals with normal serum alanine aminotransferase levels before treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970242-7

7 January 2021

Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970242-7

7 January 2021

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970242-7

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970242-7

7 January 2021

Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970242-7

7 January 2021

Virological response to interferon treatment in hepatitis C virus carriers with normal aminotransferase levels and chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970242-7

7 January 2021

Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: a pilot randomized controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970242-7

7 January 2021

Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970242-7

7 January 2021

Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. The Hepatitis C Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970242-7

7 January 2021

Interferon for non-A, non-B chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970242-7

7 January 2021

Chronic hepatitis C in patients with normal or near normal alanine aminotransferase levels: the role of interferon alpha 2b therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1089-3261%2805%2970242-7

7 January 2021

10.1016/S1089-3261(05)70242-7

Identifiers

DOI

1 reference

31 July 2017

1 reference